The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases

Affiliations

¹ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
² Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, United States of America; Department of Medicine (Infectious Diseases), Albert Einstein College of Medicine, New York, New York, United States of America.

Review

Arturo Casadevall et al. PLoS Pathog. 2015.

. 2015 Apr 23;11(4):e1004717.

doi: 10.1371/journal.ppat.1004717. eCollection 2015 Apr.

¹ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
² Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, United States of America; Department of Medicine (Infectious Diseases), Albert Einstein College of Medicine, New York, New York, United States of America.

No abstract available

Conflict of interest statement

The authors have declared that no competing interests exist.

1. Casadevall A, Scharff MD (1995) Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 21: 150–161. - PMC - PubMed
1. Update: Ebola Virus Disease Epidemic—West Africa, December 2014. MMWR Morb Mortal Wkly Rep 63: 1199–1201. - PMC - PubMed
1. Rybicki EP (2014) Plant-based vaccines against viruses. Virol J 11: 205 - PMC - PubMed
1. Almansa R, Eiros JM, Fedson D, Bermejo-Martin JF (2014) Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease? Lancet Glob Health 2: e686 10.1016/S2214-109X(14)70341-9 - DOI - PubMed
1. Casadevall A, Pirofski LA (2012) A new synthesis for antibody-mediated immunity. Nat Immunol 13: 21–28. 10.1038/ni.2184 - DOI - PMC - PubMed